APG 1252

Drug Profile

APG 1252

Alternative Names: APG-1252

Latest Information Update: 04 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ascentage Pharma
  • Class Antineoplastics
  • Mechanism of Action Bcl-X protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Small cell lung cancer; Solid tumours

Most Recent Events

  • 26 Jun 2017 China Food and Drug Administration (CFDA) approves IND for APG 1252 in Cancer
  • 27 Mar 2017 Ascentage Pharma plans a phase I trial in Solid tumours and Small cell lung cancer (Late stage disease, Metastatic disease) in Australia (ACTRN12616001597482p)
  • 17 Feb 2017 Phase-I clinical trials in Solid tumours (First-line therapy, Metastatic disease, Late-stage disease) in USA (IV) (NCT03080311)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top